InvestorsHub Logo
Followers 276
Posts 32701
Boards Moderated 0
Alias Born 11/14/2013

Re: ou71764 post# 2967

Saturday, 12/21/2013 11:24:42 AM

Saturday, December 21, 2013 11:24:42 AM

Post# of 700564
Ou,

Thanks. I stand corrected, the secondary endpoint is tumor regression. However, this still might mean a very accelerated trial in these 2 unblinded phases.

I guess I need to go back and study how they can judge adverse events for the primary endpoint. Since these are inoperable tumors, I'm stymied. I know death would be one adverse event, but....I guess if I do not find the answer, I will learn it on January 27, 2014 at NWBO's discussion. Again, it is fortunate these are open trials.


Thoughts?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News